Merck and Roche will globally promote hepatitis C treatment Victrelis (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin (peg/riba), pending marketing approvals. The companies will work together in global markets, including Europe, Asia and Latin America. The companies previously agreed to promote Victrelis in the U.S. and to explore new treatment regimens for patients with chronic HCV. Financial terms of the partnership were not disclosed. “Reac...